Trastuzumab Deruxtecan provides a HER2-targeting antibody-drug conjugate (ADC) for breast cancer and oncology research. Also known as T-DXd or DS-8201, it combines trastuzumab with deruxtecan (DXd), a potent topoisomerase I inhibitor payload and specifically supports studies of HER2-directed cytotoxicity, DNA damage, targeted drug delivery, and antibody-mediated cancer cell targeting.
Key Features and Benefits
- HER2-Targeting ADC: Combines the HER2-directed monoclonal antibody trastuzumab with a cytotoxic DXd payload for targeted cancer research.
- Deruxtecan Payload: Contains an exatecan-derived topoisomerase I inhibitor that specifically supports investigation of ADC-mediated cytotoxicity and DNA damage.
- HER2 Recognition: Supports investigation of HER2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable tetrapeptide linker specifically designed to facilitate intracellular DXd release following cellular uptake.
- High Drug-to-Antibody Ratio: Features an average drug-to-antibody ratio (DAR) of approximately 8, supporting studies of ADC payload loading and activity.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DXd delivery to HER2-expressing cancer cells.
- DNA Damage Mechanism: DXd inhibits topoisomerase I, promoting DNA damage and supporting studies of cancer cell death.
- Bystander Cytotoxicity: The membrane-permeable DXd payload specifically supports investigation of cytotoxic effects on neighboring tumor cells with varying HER2 expression.
Applications
- HER2-Positive Breast Cancer Research: Supports investigation of HER2-targeted ADC mechanisms in HER2-positive breast cancer models.
- HER2-Low Breast Cancer Research: Useful for studying ADC activity in breast cancer models with low HER2 expression.
- HER2-Ultralow Breast Cancer Research: Supports investigation of ADC responses in experimental models with very low HER2 expression.
- Gastric Cancer Research: Especially useful for evaluating HER2-directed ADC activity in relevant gastric and gastroesophageal cancer models.
- Non-Small Cell Lung Cancer Research: Supports investigation of ADC mechanisms in HER2-mutated or HER2-expressing NSCLC models.
- HER2-Expressing Solid Tumor Research: Useful for studying targeted cytotoxicity across relevant HER2-expressing solid tumor models.
- ADC Research: Supports studies of antibody binding, cellular uptake, intracellular processing, payload release, and cytotoxic activity.
- DNA Damage Research: Enables investigation of DXd-mediated topoisomerase I inhibition and associated DNA damage responses.
- Bystander Killing Research: Especially useful for studying payload-mediated cytotoxicity in heterogeneous tumor models.
- Comparative ADC Research: Supports comparison of HER2-targeted ADCs, linker technologies, payload classes, and drug-to-antibody ratios.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody stability, conjugate integrity, and biological activity.
Trastuzumab Deruxtecan combines HER2-directed antibody targeting with the DNA-damaging DXd payload and specifically supports HER2-positive and HER2-low breast cancer, gastric cancer, lung cancer, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
